| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Purchases of property and equipment | 100 | 89 |
| Acquisition of business, net of cash acquired | 0 | 0 |
| Net cash flows used in investing activities | -100 | -89 |
| Proceeds from note payable | 1,200 | 1,200 |
| Debt issuance costs related to note payable | 82 | 82 |
| Repayment of note payable | 900 | 686 |
| Repayment of unsecured debt | 139 | 119 |
| Net cash flows provided by financing activities | 79 | 313 |
| Effect of exchange rate changes on cash | 1 | 2 |
| Depreciation and amortization | 171 | 140 |
| Stock-based compensation | 374 | 250 |
| Amortization of debt discount | 386 | 279 |
| Amortization of right of use assets | 175 | 112 |
| Gain in fair value of contingent consideration liabilities | 0 | - |
| Other | 128 | 105 |
| Accounts receivable, net | -130 | 12 |
| Inventory | -830 | -698 |
| Prepaid expenses and other | -141 | -77 |
| Accounts payable and accrued expenses | -1,076 | -513 |
| Benefit from reversal of accrued payroll tax (note 12) | -522 | -522 |
| Gain on debt extinguishment | 38 | 38 |
| Product sales, net | 10,482 | - |
| Cost of goods sold | 5,401 | - |
| Gross profit | 5,081 | - |
| Research and development expense | 104 | - |
| Sales expense | 2,140 | - |
| Marketing expense | 1,248 | - |
| General and administrative expense | 2,506 | - |
| Benefit from reversal of accrued payroll taxes | -522 | - |
| Total operating expenses | 5,476 | - |
| Operating loss | -395 | - |
| Gain on extinguishment of debt | 38 | - |
| Other expense, net | -388 | - |
| Loss before income taxes | -745 | - |
| Income tax expense | 7 | - |
| Net loss | -752 | -370 |
| Net cash flows used in operating activities | -100 | 206 |
| Net decrease in cash | -73 | 432 |
| Cash and cash equivalents at beginning of period | 454 | - |
| Cash and cash equivalents at end of period | 381 | - |
CV Sciences, Inc. (CVSI)
CV Sciences, Inc. (CVSI)